Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging

Sponsor: University of Maryland, Baltimore

Sponsor score: 0
Inactive

ClinicalTrials ID:NCT04698564

Patient View

This pilot study evaluates the safety of metabolic MRI using Hyperpolarized 13C-Pyruvate in men aged 40-80 with suspected or confirmed prostate cancer. Participants must be planning an MRI-targeted biopsy or radical prostatectomy. The intervention involves using 13C-pyruvate to differentiate normal and abnormal metabolism, aiding in cancer diagnosis and characterization.

Patient Parameters

Program Overview

This is a two-tiered pilot study in which there will be no randomization and no placebo treatment. This study will be to perform metabolic magnetic resonance imaging on men suspected to have a prostate cancer to understand if metabolic MRI can be safely performed on this population

Eligibility Criteria

Inclusion Criteria

  1. Age greater than 40 and less than 80 years

  2. Clinical suspicion or history of prostate cancer reflected by one of the following:

    • PSA > 4ng/ml
    • Abnormal DRE exam
    • Known tissue diagnosis of prostate cancer from prior workup

  3. Patient planning to undergo either a MRI targeted biopsy or radical prostatectomy for prostate cancer workup or treatment

Exclusion Criteria

  1. Inability to undergo MRI scan
  2. Inability to receive IV contrast as per institutional protocol.

Get This Program In Your Inbox

You can sign up and apply your patients for this program.